Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial
Background IgA nephropathy is the most common primary GN. Clinical features of IgA nephropathy include proteinuria, which is the strongest known surrogate of progression to kidney failure. Complement pathway activation is a critical driver of inflammation and tissue injury in IgA nephropathy. Cemdis...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | angielski |
| Wydane: |
2024
|
| Dostęp online: | https://doi.org/10.2215/cjn.0000000000000384 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|